Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users.

Bakhriansyah M, Souverein PC, van den Hoogen MWF, de Boer A, Klungel OH.

Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1355-1362. doi: 10.2215/CJN.14331218. Epub 2019 Aug 15.

PMID:
31416888
2.

Successful Treatment of Severe Hyperammonaemia with Ultra-High Dose Continuous Veno-Venous Haemodiafiltration.

Boer DP, Mourik SL, van den Hoogen MWF, Langendonk JG, de Geus HRH.

Blood Purif. 2019 May 3:1-3. doi: 10.1159/000499829. [Epub ahead of print]

PMID:
31055565
3.

Nanoparticle Release by Extended Criteria Donor Kidneys During Normothermic Machine Perfusion.

Woud WW, Merino A, Hoogduijn MJ, Boer K, van den Hoogen MWF, Baan CC, Minnee RC.

Transplantation. 2019 May;103(5):e110-e111. doi: 10.1097/TP.0000000000002642. No abstract available.

PMID:
31033854
4.

Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome.

van den Hoogen MW, Steenbergen EJ, Baas MC, Florquin S, Hilbrands LB.

Transplant Direct. 2017 Mar 10;3(4):e143. doi: 10.1097/TXD.0000000000000659. eCollection 2017 Apr.

5.

Cytokine Release After Treatment With Rituximab in Renal Transplant Recipients.

Kamburova EG, van den Hoogen MW, Koenen HJ, Baas MC, Hilbrands LB, Joosten I.

Transplantation. 2015 Sep;99(9):1907-11. doi: 10.1097/TP.0000000000000515.

PMID:
25675201
6.

Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.

van den Hoogen MW, Kamburova EG, Baas MC, Steenbergen EJ, Florquin S, M Koenen HJ, Joosten I, Hilbrands LB.

Am J Transplant. 2015 Feb;15(2):407-16. doi: 10.1111/ajt.13052.

7.

Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.

Kamburova EG, Koenen HJ, van den Hoogen MW, Baas MC, Joosten I, Hilbrands LB.

PLoS One. 2014 Nov 13;9(11):e112658. doi: 10.1371/journal.pone.0112658. eCollection 2014.

8.

Anti-B cell therapy with rituximab as induction therapy in renal transplantation.

Joosten I, Baas MC, Kamburova EG, van den Hoogen MW, Koenen HJ, Hilbrands LB.

Transpl Immunol. 2014 Oct;31(4):207-9. doi: 10.1016/j.trim.2014.09.011. Epub 2014 Sep 28.

PMID:
25270152
9.

The effects of in vivo B-cell depleting therapy on ex-vivo cytokine production.

Smeekens SP, van den Hoogen MW, Kamburova EG, van de Veerdonk FL, Joosten I, Koenen HJ, Netea MG, Hilbrands LB, Joosten LA.

Transpl Immunol. 2013 Jun;28(4):183-8. doi: 10.1016/j.trim.2013.04.008. Epub 2013 May 4.

PMID:
23651756
10.

Insulin requirement after a renal transplant in patients with type 2 diabetes: the choice of calcineurin inhibitors.

van den Hoogen MW, van der Hoeven AM, Hilbrands LB.

Exp Clin Transplant. 2013 Jun;11(3):234-8. doi: 10.6002/ect.2012.0221. Epub 2013 Feb 22.

11.

Effect of a single intraoperative high-dose ATG-Fresenius on delayed graft function in donation after cardiac-death donor renal allograft recipients: a randomized study.

van den Hoogen MW, Kho MM, Abrahams AC, van Zuilen AD, Sanders JS, van Dijk M, Hilbrands LB, Weimar W, Hoitsma AJ.

Exp Clin Transplant. 2013 Apr;11(2):134-41. doi: 10.6002/ect.2012.0220. Epub 2013 Feb 22.

12.

Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab.

van den Hoogen MW, Hesselink DA, van Son WJ, Weimar W, Hilbrands LB.

Am J Transplant. 2013 Jan;13(1):192-6. doi: 10.1111/j.1600-6143.2012.04328.x. Epub 2012 Nov 21.

13.

Idiopathic giant oesophageal ulcer and leucopoenia after renal transplantation.

van Boekel GA, Volbeda M, van den Hoogen MW, Hilbrands LB, Berden JH.

Neth J Med. 2012 Oct;70(8):370-3.

14.

Three-year outcomes of belatacept studies; reason to be optimistic?

van den Hoogen MW, Pipeleers L.

Am J Transplant. 2012 Aug;12(8):2259; discussion 2260. doi: 10.1111/j.1600-6143.2012.04165.x. Epub 2012 Jul 3. No abstract available.

15.

Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.

van den Hoogen MW, Hoitsma AJ, Hilbrands LB.

Expert Opin Biol Ther. 2012 Aug;12(8):1031-42. doi: 10.1517/14712598.2012.689278. Epub 2012 May 15. Review.

PMID:
22583145
16.

[Reimbursement for alternative medical treatment in the Netherlands, incomprehensible].

van den Hoogen MW, Popa C, Elving LD, van der Meer JW.

Ned Tijdschr Geneeskd. 2012;156(6):A4227. Dutch.

PMID:
22316681
17.

Use of monoclonal antibodies in renal transplantation.

van den Hoogen MW, Hilbrands LB.

Immunotherapy. 2011 Jul;3(7):871-80. doi: 10.2217/imt.11.72. Review.

18.

Single-dose rituximab as induction in renal transplantation.

van den Hoogen MW, Hilbrands LB.

Transplantation. 2010 May 27;89(10):1295; author reply 1295. doi: 10.1097/TP.0b013e3181d368c6. No abstract available.

PMID:
20555227
19.

More on B-cell-depleting induction therapy and acute cellular rejection.

van den Hoogen MW, Hilbrands LB.

N Engl J Med. 2009 Sep 17;361(12):1215; author reply 1215-6. No abstract available.

PMID:
19771606
20.

Use of the platelet function analyzer to minimize bleeding complications after renal biopsy.

van den Hoogen MW, Verbruggen BW, Polenewen R, Hilbrands LB, Nováková IR.

Thromb Res. 2009;123(3):515-22. doi: 10.1016/j.thromres.2008.07.001. Epub 2008 Aug 13.

PMID:
18703219
21.

[Relief for surviving relatives following a suicide].

van den Hoogen MW.

Ned Tijdschr Geneeskd. 2006 Jun 17;150(24):1361; author reply 1361-2. Dutch. No abstract available.

PMID:
16808369

Supplemental Content

Loading ...
Support Center